Compare TGHL & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGHL | PLUR |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.5M |
| IPO Year | 2024 | 2026 |
| Metric | TGHL | PLUR |
|---|---|---|
| Price | $0.79 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.5K | 12.9K |
| Earning Date | 05-15-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.90 |
| 52 Week High | $2.48 | $4.87 |
| Indicator | TGHL | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 29.34 |
| Support Level | $0.33 | $0.90 |
| Resistance Level | $0.88 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 58.99 | 32.26 |
The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.